These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 32552685

  • 1. A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.
    Borja-Tabora CFC, Peyrani P, Webber C, Van der Wielen M, Cheuvart B, De Schrevel N, Bianco V, Aris E, Cutler M, Li P, Perez JL.
    BMC Infect Dis; 2020 Jun 18; 20(1):426. PubMed ID: 32552685
    [Abstract] [Full Text] [Related]

  • 2. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
    Borja-Tabora CF, Montalban C, Memish ZA, Boutriau D, Kolhe D, Miller JM, Van der Wielen M.
    BMC Infect Dis; 2015 Oct 06; 15():409. PubMed ID: 26437712
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine.
    Quiambao B, Peyrani P, Li P, Cutler MW, Van Der Wielen M, Perez JL, Webber C.
    Hum Vaccin Immunother; 2020 Jun 02; 16(6):1272-1279. PubMed ID: 32401600
    [Abstract] [Full Text] [Related]

  • 4. Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children.
    Vesikari T, Forsten A, Laudat F, Li P, Van Der Wielen M, Hezareh M, Perez JL, Webber C.
    Vaccine; 2020 May 08; 38(22):3902-3908. PubMed ID: 32284274
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
    Dbaibo G, El-Ayoubi N, Ghanem S, Hajar F, Bianco V, Miller JM, Mesaros N.
    Drugs Aging; 2013 May 08; 30(5):309-19. PubMed ID: 23494214
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
    Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM.
    Pediatr Infect Dis J; 2015 Dec 08; 34(12):e298-307. PubMed ID: 26780033
    [Abstract] [Full Text] [Related]

  • 7. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM.
    Vaccine; 2017 Aug 24; 35(36):4753-4760. PubMed ID: 28647167
    [Abstract] [Full Text] [Related]

  • 8. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Knol MJ, Stoof SP, Sanders EAM, Berbers GAM.
    Vaccine; 2017 Aug 24; 35(36):4745-4752. PubMed ID: 28668575
    [Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA, Greenberg DP, Hedrick J, Pichichero M, Decker MD, Saunders M.
    Vaccine; 2016 Oct 17; 34(44):5273-5278. PubMed ID: 27642132
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods.
    Klein NP, Block SL, Essink B, Barbi S, Smolenov I, Keshavan P.
    Vaccine; 2019 Jul 26; 37(32):4460-4467. PubMed ID: 31279564
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.
    Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM.
    Hum Vaccin Immunother; 2012 Dec 01; 8(12):1892-903. PubMed ID: 23032159
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
    Nolan T, Booy R, Marshall HS, Richmond P, Nissen M, Ziegler JB, Baine Y, Traskine M, Jastorff A, Van der Wielen M.
    Pediatr Infect Dis J; 2019 Jun 01; 38(6):643-650. PubMed ID: 31116180
    [Abstract] [Full Text] [Related]

  • 20. A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.
    Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM.
    Hum Vaccin Immunother; 2012 Dec 01; 8(12):1882-91. PubMed ID: 23032168
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.